Abstract: This present study was designed to find out whether the acankoreagenin showed the 
Introduction 35
Diabetes mellitus is a fatal metabolic disorder with a high global prevalence and 36 affecting multiple organ systems. It is characterized by insulin-secreting β-cells failure 37 which leading to relative or absolute insulin deficiency. Pancreatic β-cells function plays 38 5 of 24
Effect of Acankoreagenin on Kidney Function Tests in Normal and Diabetic Rats 126
The levels of BUN, creatinine, and albumin in normal and experimental groups in 127 type I diabetes rats were shown in Table 5 . There was a significantly elevation (P < 0.05) 128 the level of BUN, creatinine, and albumin during type I diabetes groups when compared to 129 normal group. At the concentration of 2 mg/kg in acankoreagenin group had the same BUN 130 level when compared to the positive control. At the concentration of 0.4 mg/kg in 131 acankoreagenin group had the same creatinine level when compared to the positive control, 132 while in 2 mg/kg acankoreagenin group had lower level than positive control. At the 133 concentration of 0.4 mg/kg in acankoreagenin group had the same albumin level when 134 compared to the positive control, while in 2 mg/kg acankoreagenin group was had lower 135 level than positive control. These suggest that acankoreagenin can improve the relieving 136 kidney damage in type I diabetes rats. 137
Effect of Acankoreagenin on TNF-α Level in Normal and Diabetic Rats 138
The level of TNF-α in normal and experimental groups in type I diabetes rats were 139 shown in Figure 3 . There was a significantly elevation (P < 0.05) the level of TNF-α during 140 type I diabetes groups when compared to normal group. The positive control had much 141 decreased the TNF-α level, but it was significantly higher (P < 0.05) than compared to the 142 normal group. At the concentration of 2 mg/kg in acankoreagenin group was significantly 143 decreased (P < 0.01) when compared to the normal group. 144
Effect of Acankoreagenin on the Oxidative Stress Biomarkers in Normal and Diabetic 145
Rats 146
The levels of GSH, MDA, and SOD in normal and experimental groups in type I 147 diabetes rats were shown in Table 6 . There was a significantly elevation (P < 0.05) the level 148 of MDA while the level of GSH, and SOD decreased during type I diabetes groups when 149 compared to normal group. At the concentration of 0.4 mg/kg in acankoreagenin group had 150 the same GSH level when compared to the positive control, while in 2 mg/kg in 151 acankoreagenin group had higher level than positive control. At the concentration of 0.4 152 mg/kg in acankoreagenin group had the same MDA level when compared to the positive 153 control, while in 2 mg/kg acankoreagenin group was had lower level than positive control. 154
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At the concentration of 2 mg/kg in acankoreagenin group was had higher SOD level than 155 positive control while it was significantly lower (P < 0.05) than compared to the normal 156 group. These suggest that acankoreagenin can improve in kidney oxidative stress in type I 157 diabetes rats. 158
Effect of Acankoreagenin on NF-kB Expressions in Normal and Diabetic Rats 159
Pancreas 160 NF-κB and I-κBα expression in the pancreas tissues from each group were shown in 161 Figure 4 . NF-κB expression in the control group showed much higher than those in the 162 normal group, while I-κBα expression showed much lower than those in the normal group. 163
At the concentration of 2 mg/kg in acankoreagenin group showed a higher I-κBα expression 164 and lower NF-κB expression than positive control group. 165
Effect of Acankoreagenin on TGF-β1 Expressions in Normal and Diabetic Rats Kidney 166
NF-κB, p-p38 and TGF-β1 expression in the kidney tissues from each group were 167 shown in Figure 5 . NF-κB, p-p38 and TGF-β1 expression in control group showed much 168 higher than those in the normal group. At the concentration of 2 mg/kg in acankoreagenin 169 group showed a low expression in NF-κB, p-p38 and TGF-β1. 170
Effect of Acankoreagenin on Histopathological Findings in Normal and Diabetic Rats 171

Pancreas and Kidney 172
The effect of acankoreagenin ameliorated the pancreas histopathology as shown is 173 Figure 6 . Three weeks after the establishment of the diabetes model, the diabetic rats 174 showed severely damaged Langerhans islets were visible compared to normal rats. In 175 diabetic rats with acankoreagenin treatment, high-dose of concentration was reduced 176
Langerhans islets damaged, necrosis or inflammation when compared to the normal rats. 177
The effect of acankoreagenin ameliorated the renal histopathology as shown is Fig.  178 7. Three weeks after the establishment of the diabetes model, the diabetic rats showed 179 severely damaged glomerulus was visible compared to normal rats. In diabetic rats with 180 acankoreagenin treatment, high-dose of acankoreagenin was reduced glomerulus damaged. 181
Especially, it showed a better renoprotective effect when compared to positive control rats. 182 7 of 24 STZ-induced diabetes is characterized by pancreatic β-cell damage and insufficient 184 insulin synthesis [22] , which are all related to oxyradicals. In this study, sharply reduced 185 body weights and increased fasting blood glucose levels were observed in rats with STZ-186 induced type I diabetes, and significantly reversed by administration of acankoreagenin. 187
We were encouraged to find that acankoreagenin enhanced the serum levels of insulin, 188 indicating their amelioration of the metabolic disturbance of glucose enzymes and had 189 renoprotective effect in diabetic rats. of liver pathology, as evidenced hepatic. The increase of ALT and AST activity in STZ 213 intoxication has been reported previously, and was confirmed in the present study [27] . 214
However, further investigations are needed to clarify the detailed roles of the oxidative 215 system in acankoreagenin-mediated antidiabetic activity. 216 DN is a major cause of end-stage renal disease, can be defined as progressive reduction 217 in the glomerular filtration rate, increased proteinuria, and tubulointerstitial fibrosis due to 218 renal pathological changes. Renal fibrosis is a common consequence of DN and other 219 chronic kidney diseases, and may eventually lead to serious clinical complications and 220 dysfunction [28, 29] . Compared with the diabetic control group, the renoprotective effect of 221 acankoreagenin was manifested by normalization of BUN, creatinine, and albumin levels. 222
Major antioxidant enzymes, such as SOD and GSH, are thought to be the first line of 223 defense against ROS produced by peroxide decomposition during oxidative stress, while 224 blocking lipid peroxidation [30] . The content of MDA is an important indicator of oxidative 225 stress, and its formation is promoted in the kidney by reactive oxy gen species (ROS). 226
Antioxidants can effectively alleviate the symptoms of diabetes and DN [31] . In the present 227 study, the levels of SOD and GSH showed a significantly increased and a strong reduction 228 in MDA concentration after a 3-week treatment with acankoreagenin. 229 NF-κB, such as TNF-α and IL-1β, is a transcription factor involved in cellular response 230 and regulates the expression of inflammatory cytokines. Activation of NF-κB contributes 231 to the gradual decrease of β-cells during diabetes, whereas blocking this process protects β-232 cells against cytokine-induced apoptosis [32] . In diabetes patients, increased NF-κB levels 233 in many tissues have been observed. Via inhibition of NF-κB activities transferrin 234 effectively suppressed the intracellular signaling essential for I-κB gene expression [33] . 235 
Material and Methods 255
Plant Materials and Isolation of Acankoreagenin from LAG 256
The LAG were collected at Changsha, Hunan province, China, in October 2015 and 257 confirmed by Professor Liu xiangqian at the Hunan University of Chinese Medicine. A 258 voucher specimen (no.20151006) was deposited in the authorized laboratory. The following 259 isolation method of acankoreagenin from LAG was described by Liu xiangqian [37] . The 260 dried leaves of the plant (500 g) were extracted repeatedly with hot MeOH to give an extract 261 (71.36 g), which was chromatographed on Diaion HP-20P column by using gradient elution 262 with H2O, 30 % MeOH, 50 % MeOH, 80 % MeOH and MeOH. A saponin mixture eluted 263 with 80 % MeOH was evap-orated to dryness in vacuo, and was subsequently 264 chromatographed on a silica gel by using gradi-ent elution with V (CHCl3) : V (MeOH) : V 265 (H2O) =9 : 1 : 0.1→7 : 3 : 0.5 to give seven fractions. Fr.2 was chromatographed again on 266 silica gel column using V (CHCl3): V (MeOH): V (H2O) = 9: 1: 0.1→8: 2: 0.2 to obtain 267 compound 1 (3.59 g). The chemical structure of compound 1 was characterized on the basis 268 of 1 H-and 13 C-NMR spectral analysis, and comparisons with published spectral data. The 269 purity of the compounds was over 98%. The chemical structure of acankoreagenin was shown 270 in Figure 9 . 271
Animals and Experimental Group Design 272
Adult male Sprague-Dawly (SD) rats, 6 weeks (190-210 g) were purchased from 273 Samtako (Osan, Korea), 3 animals per cage, rats were housed in a laminar flow cabinet with 274 a 12-h light/dark cycle (06:00-18:00 h) and temperature (23.0 ± 1 °C). All animals were 275 maintained on standard laboratory chow ad libitum. Food and water intake were evaluated 276 daily, and measured body weight weekly. After one week of adaptation, the animals were 277 divided into six groups (n = 6 animals/group); (N) normal, non-diabetic group; (C) control, 
Sample Treatment 290
All the groups were treated daily with orally administered by via gavage for 3 weeks. 291
The samples were diluted in 0.2% carboxymethyl cellulose (CMC) and treated daily with 292 orally administered. The dilution was performed immediately prior to the intragastric 293 administration. Rats from non-treated groups received vehicle solution (0.2% CMC) 294 without sample. The treatment occurred between 10:00 and 11:00 a.m. 295
OGTT 296
An overnight fast, oral glucose load was administered via gavage 2 g/kg of body 297
weight. Blood glucose levels were measured from tail bleeds. To assess the fasting blood 298 glucose levels, blood samples were collected from each subject at 0, 30, 60 and 120 min 299 after administration of glucose. 300
Determination of Plasma Insulin, HbA1c and C-peptide 301
Plasma insulin level was assayed using with rat insulin ELISA kit (ALPCO Co). 302 Plasma HbA1c level was assayed using with Rat Glycated hemoglobin A1c ELISA Kit 303 (Cusabio Biotech Co., Ltd., WH, HB, China). Serum C-peptide level was assayed using 304 with rat C-peptide ELISA kit (ALPCO Co). 305
Blood Biochemical Parameters 306
Blood samples were used for measurement of aspartate transaminase (AST), alanine 307 transaminase (ALT), Total Bilirubin (T-Bil), Total Cholesterol (T-Chol), HDL-Cholesterol 308 (H-Chol) and Triglyceride (TG) were using with clinical chemistry test instrument 309 (Spotchem Ez, koka, konan, Japan). 310
KidneyFfunction Tests 311
Plasma creatinine was assayed using with creatinine detection kit (Arbor assay). Serum 312 albumin was assayed using with rat albumin ELISA kit (Shibayagi, Shibukawa, Gunma, 313 Japan). Blood urea nitrogen (BUN) was assayed using clinical chemistry test instrument. 314
Kidney Tumor Necrosis Factor-Alpha (TNF-α) level 315
TNF-α level in kidney was assessed using with rat TNF-α ELISA kit (BD Biosciences, 316
San Diego, CA, USA). 317
Oxidative Stress Biomarkers 318
Kidney reduced glutathione (GSH) content was assayed using with GSH detection kit 319 (Enzo, Farmingdale, NY, USA). Kidney malondialdehyde (MDA) was assayed using with 320 lipid peroxidation (MDA) assay kit (Sigma-Aldrich). Serum superoxide dismutase (SOD) 321 activity was assayed using with SOD (Sigma-Aldrich) assay kit. 322
Western Blotting Analysis 323
Take each group the frozen kidney and pancreas tissue were homogenized in lysis 324 buffer (iNtRON Biotech) on ice and the centrifuged 17,000 rpm for 10 min at 4 . The ℃ 325 resultant protein extracts were denatured and separated by SDS-PAGE and then transferred 326 to PVDF membranes for 2 h. Membranes were blocked in 5% skim milk and probed with 327 primary antibodies (1 μg/ml) against I-κBα, iNOS, Beverly, 328 MA, USA) p-38, TGF-β1 (Santa Cruz, CA, USA) were incubated overnight at 4 . Then ℃ 329 the membranes were incubated with anti-rabbit or anti-mouse IgG antibodies for 2 h at 330 room temperature. Reactive bands were visualized using ECL reagent and protein 331 expressions were analyzed by the signals captured on the PVDF membranes using a Fluor 332
Cheme E image analysis. to block non-specific staining. Digital images from the pancreas and kidney using 40 digital 341 images (100 magnification) from each group. 342
Statistical Analysis 343
All experiments were performed in triplicate. Dates were analyzed using the SPSS 344 control groups were performed using Student's t-test. And comparisons between multiple 347 groups were made by ANOVA and Duncan's tests. Differences with a p value <0.05 were 348 considered statistically significant. 349
Conclusions 350
In conclusion, the ability of acankoreagenin to decrease blood glucose levels in STZ-351 induced type I diabetic rats towards normal levels confirms its antidiabetic activity. It also 
